Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 155 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Fountzilas, George  [Clear All Filters]
Journal Article
Carvajal-Hausdorf, D. E., Schalper K. A., Pusztai L., Psyrri A., Kalogeras K. T., Kotoula V., et al. (2015).  Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.. J Natl Cancer Inst. 107(8), 
Polychronidou, G., Kotoula V., Manousou K., Kostopoulos I., Karayannopoulou G., Vrettou E., et al. (2018).  Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.. PLoS One. 13(12), e0208221.
Fountzilas, G., Kalogera-Fountzila A., Lambaki S., Wirtz R. M., Nikolaou A., Karayannopoulou G., et al. (2009).  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.. J Oncol. 2009, 305908.
Murray, S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. (2012).  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.. J Exp Clin Cancer Res. 31, 77.
Bojesen, S. E., Pooley K. A., Johnatty S. E., Beesley J., Michailidou K., Tyrer J. P., et al. (2013).  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.. Nat Genet. 45(4), 371-84, 384e1-2.
Fostira, F., Thodi G., Sandaltzopoulos R., Fountzilas G., & Yannoukakos D. (2010).  Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients.. BMC Cancer. 10, 389.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Pancoska, P., Kirkwood J. M., Bouros S., Spyropoulou-Vlachou M., Pectasides E., Tsoutsos D., et al. (2014).  A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.. PLoS One. 9(1), e86375.
Pentheroudakis, G., Pavlidis N., Fountzilas G., Krikelis D., Goussia A., Stoyianni A., et al. (2013).  Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.. Mol Cancer. 12, 57.
Pectasides, E., Egloff A-M., Sasaki C., Kountourakis P., Burtness B., Fountzilas G., et al. (2010).  Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.. Clin Cancer Res. 16(8), 2427-34.
Lazaridis, G., Kotoula V., Vrettou E., Kostopoulos I., Manousou K., Papadopoulou K., et al. (2019).  Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer.. Cancer Genomics Proteomics. 16(3), 195-206.
Kotoula, V., & Fountzilas G. (2016).  Overview of advances in cancer immunotherapy.. Ann Transl Med. 4(14), 260.
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Gogas, H., Pectasides D., Kostopoulos I., Lianos E., Skarlos D., Papaxoinis G., et al. (2010).  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.. Clin Breast Cancer. 10(3), 230-7.
Koumarianou, A., Karayannopoulou G., Gourgioti G., Batistatou A., Bobos M., Efstratiou I., et al. (2015).  PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.. Cancer Chemother Pharmacol. 75(6), 1289-301.
Kotoula, V., Lakis S., Tikas I., Giannoulatou E., Lazaridis G., Papadopoulou K., et al. (2019).  Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.. Gynecol Oncol. 152(2), 375-386.
Fountzilas, E., Kotoula V., Koliou G-A., Giannoulatou E., Gogas H., Papadimitriou C., et al. (2020).  Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.. Oncotarget. 11(1), 1-14.
Skarlos, D. V., Timotheadou E., Galani E., Samantas E., Grimani I., Lianos E., et al. (2009).  Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic C. Oncology. 77(2), 107-12.
Karavasilis, V., Kotoula V., Pentheroudakis G., Televantou D., Lambaki S., Chrisafi S., et al. (2013).  A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.. J Neurol. 260(6), 1469-80.
Briasoulis, E., Golfinopoulos V., Karina M., Papakostas P., Pavlidis N., & Fountzilas G. (2010).  Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.. Anticancer Drugs. 21(8), 785-9.
Razis, E., Selviaridis P., Labropoulos S., Norris J. L., Zhu M-J., Song D. D., et al. (2009).  Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.. Clin Cancer Res. 15(19), 6258-66.
Papaxoinis, G., Kotoula V., Giannoulatou E., Koliou G-A., Karavasilis V., Lakis S., et al. (2018).  Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.. Med Oncol. 35(7), 101.
Escudier, B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S. F., et al. (2009).  Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.. J Clin Oncol. 27(25), 4068-75.
Fountzilas, G., Fragkoulidi A., Kalogera-Fountzila A., Nikolaidou M., Bobos M., Calderaro J., et al. (2010).  A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.. Cancer Chemother Pharmacol. 65(4), 649-60.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές